{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:29:10Z","timestamp":1773696550095,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>While excess adiposity is a known risk factor for incident heart failure ( HF), once the condition is established, observational data suggest that increased body mass index (BMI) may confer a survival advantage. This paradox has emphasized the underlying roles of cardiorespiratory fitness (CRF), and body composition, particularly lean mass (LM), in influencing clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>In this review, we explore the multifaceted nature of the obesity paradox in HF, with a focus on emerging anti-obesity incretin-mimetic therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1\/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These agents have demonstrated remarkable efficacy in weight reduction and favorable cardiovascular profiles in patients with HF with preserved ejection fraction (EF), yet their use in other HF populations, such as HF with reduced EF, raises important clinical questions and the urgent need for future research. Concerns include the potential for LM loss, implications for sarcopenic obesity, and the uncertain impact of weight loss on outcomes in patients who may not benefit from weight loss. We also highlight the need to assess therapeutic outcomes beyond BMI, incorporating measures of CRF, such as peak oxygen consumption (VO\u2082 peak), quality of life, and functional capacity, using tools such as the 6-minute walk test. Barriers to implementation, including cost, provider hesitation, insurance restrictions, and patient level challenges are also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Finally, we call for future research using contemporary cohorts and advanced phenotyping to reevaluate the obesity paradox in the context of modern pharmacologic interventions. As obesity treatment continues to evolve, a patient-centered, individualized approach that integrates body composition, functional status, and comorbid conditions will be essential in optimizing care for individuals with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-025-02333-5","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:27:53Z","timestamp":1765888073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review"],"prefix":"10.1007","volume":"28","author":[{"given":"Pamela L.","family":"Alebna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Martey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"10481","key":"2333_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"2025","unstructured":"Ng M, Gakidou E, Lo J, et al. Global, regional, and National prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021. Lancet. 2025;405(10481):813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1.","journal-title":"Lancet"},{"key":"2333_CR2","doi-asserted-by":"publisher","first-page":"102882","DOI":"10.1016\/j.pmedr.2024.102882","volume":"46","author":"ANMS Islam","year":"2024","unstructured":"Islam ANMS, Sultana H, Nazmul HR, Md, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from steps survey of WHO member states: A meta-analysis. Prev Med Rep. 2024;46:102882. https:\/\/doi.org\/10.1016\/j.pmedr.2024.102882.","journal-title":"Prev Med Rep"},{"key":"2333_CR3","doi-asserted-by":"publisher","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. https:\/\/doi.org\/10.1016\/j.metabol.2022.155217.","journal-title":"Metabolism"},{"issue":"11","key":"2333_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae176","volume":"8","author":"K Autret","year":"2024","unstructured":"Autret K, Bekelman TA. Socioeconomic status and obesity. J Endocr Soc. 2024;8(11):bvae176. https:\/\/doi.org\/10.1210\/jendso\/bvae176.","journal-title":"J Endocr Soc"},{"key":"2333_CR5","unstructured":"Obesity and overweight. Accessed May 25. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"2333_CR6","unstructured":"The skyrocketing cost of weight-loss drugs has state Medicaid programs looking for a solution. AP News. April 6. 2025. Accessed May 25, 2025. https:\/\/apnews.com\/article\/ozempic-wegovy-medicaid-weight-loss-glp1-dd34e5d76b660550dad73dc3069083ce"},{"key":"2333_CR7","doi-asserted-by":"publisher","first-page":"581461","DOI":"10.3389\/fped.2020.581461","volume":"8","author":"AR Kansra","year":"2021","unstructured":"Kansra AR, Lakkunarajah S, Jay MS. Childhood and adolescent obesity: a review. Front Pediatr. 2021;8:581461. https:\/\/doi.org\/10.3389\/fped.2020.581461.","journal-title":"Front Pediatr"},{"key":"2333_CR8","unstructured":"What is the Gold Standard for determining Body Fat? Obesity Medicine Association. Accessed May 25. 2025. https:\/\/obesitymedicine.org\/blog\/what-is-the-gold-standard-for-determining-body-fat\/"},{"issue":"3","key":"2333_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13679-024-00580-1","volume":"13","author":"K Sweatt","year":"2024","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584\u201395. https:\/\/doi.org\/10.1007\/s13679-024-00580-1.","journal-title":"Curr Obes Rep"},{"issue":"10","key":"2333_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","volume":"126","author":"JP Despr\u00e9s","year":"2012","unstructured":"Despr\u00e9s JP. Body fat distribution and risk of cardiovascular disease. Circulation. 2012;126(10):1301\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.067264.","journal-title":"Circulation"},{"issue":"4","key":"2333_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pcad.2013.10.003","volume":"56","author":"E Oliveros","year":"2014","unstructured":"Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56(4):426\u201333. https:\/\/doi.org\/10.1016\/j.pcad.2013.10.003.","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"2333_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ejhf.1956","volume":"22","author":"VN Rao","year":"2020","unstructured":"Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(9):1540. https:\/\/doi.org\/10.1002\/ejhf.1956.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2333_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"21","key":"2333_CR14","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-1010. https:\/\/doi.org\/10.1161\/CIR.0000000000000973.","journal-title":"Circulation"},{"issue":"5","key":"2333_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa020245","volume":"347","author":"E Kenchaiah Satish","year":"2002","unstructured":"Kenchaiah Satish E, Jane C, Daniel L, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020245.","journal-title":"N Engl J Med"},{"issue":"3","key":"2333_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0735-1097(01)01448-6","volume":"38","author":"TB Horwich","year":"2001","unstructured":"Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. JACC. 2001;38(3):789\u201395. https:\/\/doi.org\/10.1016\/S0735-1097(01)01448-6.","journal-title":"JACC"},{"issue":"2","key":"2333_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.mayocp.2016.11.001","volume":"92","author":"S Carbone","year":"2017","unstructured":"Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92(2):266\u201379. https:\/\/doi.org\/10.1016\/j.mayocp.2016.11.001.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2333_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.106.679779","volume":"116","author":"S Kenchaiah","year":"2007","unstructured":"Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure. Circulation. 2007;116(6):627\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.679779.","journal-title":"Circulation"},{"issue":"7","key":"2333_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0002-9149(03)00031-6","volume":"91","author":"CJ Lavie","year":"2003","unstructured":"Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003;91(7):891\u20134. https:\/\/doi.org\/10.1016\/S0002-9149(03)00031-6.","journal-title":"Am J Cardiol"},{"key":"2333_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2022.11.013","volume":"78","author":"AW Tutor","year":"2023","unstructured":"Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2023;78:2\u201310. https:\/\/doi.org\/10.1016\/j.pcad.2022.11.013.","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"2333_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.amjcard.2015.02.024","volume":"115","author":"A Sharma","year":"2015","unstructured":"Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115(10):1428\u201334. https:\/\/doi.org\/10.1016\/j.amjcard.2015.02.024.","journal-title":"Am J Cardiol"},{"key":"2333_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2025.03.030","author":"CJ Lavie","year":"2025","unstructured":"Lavie CJ, Tutor AW, Carbone S. Is the obesity paradox real? Can J Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.cjca.2025.03.030.","journal-title":"Can J Cardiol"},{"issue":"9363","key":"2333_CR23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","volume":"361","author":"SD Anker","year":"2003","unstructured":"Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(03)12892-9.","journal-title":"Lancet"},{"issue":"4","key":"2333_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.pcad.2015.12.003","volume":"58","author":"CJ Lavie","year":"2016","unstructured":"Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016;58(4):393\u2013400. https:\/\/doi.org\/10.1016\/j.pcad.2015.12.003.","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"2333_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/ejhf.2832","volume":"25","author":"S Carbone","year":"2023","unstructured":"Carbone S, Elagizi A, Lavie CJ. Better pharmacotherapy in heart failure with reduced ejection fraction may partly explain the obesity paradox. Eur J Heart Fail. 2023;25(5):711\u20133. https:\/\/doi.org\/10.1002\/ejhf.2832.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2333_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/eurjpc\/zwad140","volume":"30","author":"S Prausm\u00fcller","year":"2023","unstructured":"Prausm\u00fcller S, Weidenhammer A, Heitzinger G, et al. Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander? Eur J Prev Cardiol. 2023;30(12):1247\u201354. https:\/\/doi.org\/10.1093\/eurjpc\/zwad140.","journal-title":"Eur J Prev Cardiol"},{"key":"2333_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.743327","volume":"8","author":"L Guo","year":"2022","unstructured":"Guo L, Liu X, Yu P, Zhu W. The \u201cobesity paradox\u201d in patients with HFpEF with or without comorbid atrial fibrillation. Front Cardiovasc Med. 2022;8:743327. https:\/\/doi.org\/10.3389\/fcvm.2021.743327.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2333_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.122.059280","volume":"146","author":"S Rosch","year":"2022","unstructured":"Rosch S, Kresoja KP, Besler C, et al. Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation. 2022;146(7):506\u201318. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059280.","journal-title":"Circulation"},{"issue":"10","key":"2333_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"issue":"3","key":"2333_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","volume":"4","author":"M Haass","year":"2011","unstructured":"Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction. Circ Heart Fail. 2011;4(3):324\u201331. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.110.959890.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"2333_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268\u201377. https:\/\/doi.org\/10.1001\/jama.2013.2024.","journal-title":"JAMA"},{"issue":"7","key":"2333_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.115.016801","volume":"133","author":"D Aune","year":"2016","unstructured":"Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality. Circulation. 2016;133(7):639\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016801.","journal-title":"Circulation"},{"issue":"18","key":"2333_CR33","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;81(18):1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049.","journal-title":"J Am Coll Cardiol"},{"key":"2333_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133182","volume":"430","author":"MM Rodrigues","year":"2025","unstructured":"Rodrigues MM, Falc\u00e3o LM. Pathophysiology of heart failure with preserved ejection fraction in overweight and obesity - clinical and treatment implications. Int J Cardiol. 2025;430:133182. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133182.","journal-title":"Int J Cardiol"},{"issue":"24","key":"2333_CR35","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1161\/CIR.0000000000000461","volume":"134","author":"R Ross","year":"2016","unstructured":"Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American heart association. Circulation. 2016;134(24):e653-99. https:\/\/doi.org\/10.1161\/CIR.0000000000000461.","journal-title":"Circulation"},{"issue":"13","key":"2333_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020387","volume":"10","author":"MGJ Veugen","year":"2021","unstructured":"Veugen MGJ, Linssen PBC, Henry RMA, et al. Measures of left ventricular diastolic function and cardiorespiratory fitness according to glucose metabolism status: the Maastricht study. J Am Heart Assoc. 2021;10(13):e020387. https:\/\/doi.org\/10.1161\/JAHA.120.020387.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2333_CR37","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1249\/MSS.0000000000002701","volume":"53","author":"EC Diaz","year":"2021","unstructured":"Diaz EC, Weber JL, Adams SH, Young CG, Bai S, B\u00f8rsheim E. Cardiorespiratory fitness associates with blood pressure and metabolic health of children-the Arkansas active kids study. Med Sci Sports Exerc. 2021;53(11):2225\u201332. https:\/\/doi.org\/10.1249\/MSS.0000000000002701.","journal-title":"Med Sci Sports Exerc"},{"issue":"6","key":"2333_CR38","doi-asserted-by":"publisher","first-page":"e183605","DOI":"10.1001\/jamanetworkopen.2018.3605","volume":"1","author":"K Mandsager","year":"2018","unstructured":"Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1(6):e183605. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.3605.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2333_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.mayocp.2012.11.020","volume":"88","author":"CJ Lavie","year":"2013","unstructured":"Lavie CJ, Cahalin LP, Chase P, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88(3):251\u20138. https:\/\/doi.org\/10.1016\/j.mayocp.2012.11.020.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2333_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/951582","volume":"2012","author":"PA McAuley","year":"2012","unstructured":"McAuley PA, Smith NS, Emerson BT, Myers JN. The obesity paradox and cardiorespiratory fitness. J Obes. 2012;2012(1):951582. https:\/\/doi.org\/10.1155\/2012\/951582.","journal-title":"J Obes"},{"key":"2333_CR41","doi-asserted-by":"publisher","DOI":"10.15420\/usc.2024.44","volume":"19","author":"J Lopez","year":"2025","unstructured":"Lopez J, Makuvire T, Davis JD, Carbone S. The short and sweet on sodium\u2013glucose cotransporter inhibitors and glucagon-like peptide-1 receptor agonists in heart failure. US Cardiology Review. 2025;19:e12. https:\/\/doi.org\/10.15420\/usc.2024.44.","journal-title":"US Cardiology Review"},{"issue":"6","key":"2333_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jacc.2017.12.014","volume":"71","author":"M Pareek","year":"2018","unstructured":"Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic surgery. JACC. 2018;71(6):670\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2017.12.014.","journal-title":"JACC"},{"issue":"2","key":"2333_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010453","volume":"17","author":"A Mentias","year":"2024","unstructured":"Mentias A, Desai MY, Aminian A, et al. Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity. Circ Heart Fail. 2024;17(2):e010453. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.010453.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2333_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"key":"2333_CR45","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Verma S, Borlaug BA, et al. Effects of semaglutide on Symptoms, Function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial. Circulation Published Online November. 2023;12. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067505.","DOI":"10.1161\/CIRCULATIONAHA.123.067505"},{"issue":"3","key":"2333_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"24","key":"2333_CR47","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"A Lincoff","year":"2023","unstructured":"Lincoff A, Michael B-F, Kirstine, Colhoun Helen M, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"1","key":"2333_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cells13010065","volume":"13","author":"SS Wilbon","year":"2023","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists\u2014effects beyond obesity and diabetes. Cells. 2023;13(1):65. https:\/\/doi.org\/10.3390\/cells13010065.","journal-title":"Cells"},{"key":"2333_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"2333_CR50","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"issue":"12","key":"2333_CR51","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"5","key":"2333_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"2333_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01160-6","author":"F Sanchis-Gomar","year":"2025","unstructured":"Sanchis-Gomar F, Neeland IJ, Lavie CJ. Balancing weight and muscle loss in GLP1 receptor agonist therapy. Nat Rev Endocrinol. 2025. https:\/\/doi.org\/10.1038\/s41574-025-01160-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"22","key":"2333_CR54","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.jacc.2016.08.072","volume":"68","author":"S Carbone","year":"2016","unstructured":"Carbone S, Canada JM, Buckley LF, et al. Obesity contributes to exercise intolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68(22):2487\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2016.08.072.","journal-title":"J Am Coll Cardiol"},{"key":"2333_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2023.112163","volume":"116","author":"H Salmons","year":"2023","unstructured":"Salmons H, Ahmed SI, Billingsley HE, et al. Skeletal muscle quality, measured via phase angle, and cardiorespiratory fitness in patients with obesity and heart failure with preserved ejection fraction. Nutrition. 2023;116:112163. https:\/\/doi.org\/10.1016\/j.nut.2023.112163.","journal-title":"Nutrition"},{"issue":"5","key":"2333_CR56","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2217\/fca-2017-0023","volume":"13","author":"S Carbone","year":"2017","unstructured":"Carbone S, Popovic D, Lavie CJ, Arena R. Obesity, body composition and cardiorespiratory fitness in heart failure with preserved ejection fraction. Future Cardiol. 2017;13(5):451\u201363. https:\/\/doi.org\/10.2217\/fca-2017-0023.","journal-title":"Future Cardiol"},{"issue":"6","key":"2333_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/HCR.0b013e3182642688","volume":"32","author":"EG Artero","year":"2012","unstructured":"Artero EG, Lee Dchul, Lavie CJ, et al. Effects of muscular strength on cardiovascular risk factors and prognosis. J Cardiopulm Rehabil Prev. 2012;32(6):351. https:\/\/doi.org\/10.1097\/HCR.0b013e3182642688.","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"10","key":"2333_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009518","volume":"15","author":"HE Billingsley","year":"2022","unstructured":"Billingsley HE, Del Buono MG, Canada JM, et al. Sarcopenic obesity is associated with reduced cardiorespiratory fitness compared with nonsarcopenic obesity in patients with heart failure with reduced ejection fraction. Circ Heart Fail. 2022;15(10):e009518. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009518.","journal-title":"Circ Heart Fail"},{"issue":"16","key":"2333_CR59","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","volume":"150","author":"J Linge","year":"2024","unstructured":"Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and Glucagon-Like Peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150(16):1288\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.067676.","journal-title":"Circulation"},{"issue":"5","key":"2333_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998\u20131004. https:\/\/doi.org\/10.2337\/dc22-1710.","journal-title":"Diabetes Care"},{"issue":"12","key":"2333_CR61","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.mayocp.2024.07.007","volume":"99","author":"R Arena","year":"2024","unstructured":"Arena R, Pronk NP, Lavie CJ. Pharma-cise in the glucagon-like peptide-1 receptor agonists era: a concept whose time has come. Mayo Clin Proc. 2024;99(12):1869\u201373. https:\/\/doi.org\/10.1016\/j.mayocp.2024.07.007.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2333_CR62","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02333-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T01:03:21Z","timestamp":1765933401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02333-5","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Lavie is on a DSMB for Novo Nordisk for their REDEFINE 3 Trial on CagriSema. The other authors do not have any industry relationships or other financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}